For over 130 years, the Abbott initiative has put science and innovation to work in line with promoting good health. Truly without good health, we are limited from exploring full possibilities in life. Like the common saying, Technology Fights HIV As Abbott’s Innovation Receives WHO Prequalification ApprovalHealth is Wealth. On Thursday, May 2, Abbott announced that the world’s first point-of-care viral load diagnostic test, m-PIMA™ HIV-1/2 VL, has received the World Health Organization’s Prequalification approval (WHO PQ). The test earlier received CE Mark last year.
Abbott is a technology company that uses technological innovations to meet health needs. Their formative mission has been to design such that their innovations help one live their best life. Abbott states ‘that’s our commitment to building life-changing technologies that keep your heart healthy, nourish your body at every stage of life, help you feel and move better, and bring you information, medicines, and breakthroughs to manage your health.’
Vice President, Infectious Disease – Emerging Markets, Rapid Diagnostics, Abbott, Damian Halloran said: “m-PIMA HIV-1/2 VL is the only truly portable molecular point-of-care test designed specifically for use in resource-limited settings such as in sub-Saharan Africa.” “With WHO PQ, global funders and ministries of health can now confidently expand access to viral load testing, reaching more people who need the test, with the most compact and efficient point-of-care HIV diagnostic platform available anywhere in the world today.”
The pioneering of Dr. Wallace C. Abbott in 1888, started off Abbott as a scientific practice of pharmacy before continuous expansion by other delegates over time. Abbott has gone from Chicago US to its first extension office in London, England. Different experts have helped the ‘Abbott’ name hit different milestones before this new inclusion.
The m-PIMA HIV-1/2 VL is easily transferable to the point of care and is designed to measure viral load in under 70 minutes, while the patient is still present. This way, patients receive results within the time they are still present for checkup. In 2011, the African continent was home to about 15.2 percent of the world’s population which is more than two-thirds of the total HIV infected persons worldwide. An estimate of 35 million people was infected Africans, of whom 15 million have already died. Sub-Saharan Africa alone accounted for about 69 percent of all people living with HIV at the time and this is alarming. Abbott’s prequalification approval is a step forward for Africa as its innovation really is useful in remote areas of sub-Saharan Africa where there’s a major public health concern for HIV/AIDS as a cause of high death rate and never enough health infrastructure.
Credit – abbott.com, Yinka Okeowo, Pulse, Wikipedia.JOIN OUR COMMUNITY